Barr’s First Biologic Product Candidate Is Adenovirus Vaccine
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is developing the product under a contract with the federal government, which sought a new manufacturer after Wyeth ceased production of its vaccine in 1996. Barr expects to file an application to market the product by 2007.